The Manufacturers Life Insurance Company increased its holdings in MediciNova, Inc. (NASDAQ:MNOV) by 1,645.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,002 shares of the biopharmaceutical company’s stock after acquiring an additional 27,340 shares during the period. The Manufacturers Life Insurance Company owned about 0.08% of MediciNova worth $187,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in MNOV. Jane Street Group LLC purchased a new position in MediciNova in the third quarter valued at approximately $118,000. Voya Investment Management LLC lifted its stake in MediciNova by 22.9% in the second quarter. Voya Investment Management LLC now owns 19,341 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 3,603 shares during the last quarter. Wells Fargo & Company MN lifted its stake in MediciNova by 63.3% in the third quarter. Wells Fargo & Company MN now owns 32,575 shares of the biopharmaceutical company’s stock valued at $208,000 after purchasing an additional 12,624 shares during the last quarter. Alps Advisors Inc. purchased a new position in MediciNova in the fourth quarter valued at approximately $259,000. Finally, Schwab Charles Investment Management Inc. lifted its stake in MediciNova by 23.3% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 57,200 shares of the biopharmaceutical company’s stock valued at $371,000 after purchasing an additional 10,800 shares during the last quarter. 18.79% of the stock is owned by institutional investors.

How to Become a New Pot Stock Millionaire

MediciNova, Inc. (NASDAQ:MNOV) opened at $11.78 on Friday. MediciNova, Inc. has a 12 month low of $4.40 and a 12 month high of $14.50.

Several equities analysts recently commented on MNOV shares. BidaskClub downgraded MediciNova from a “buy” rating to a “hold” rating in a research note on Saturday, January 20th. ValuEngine upgraded MediciNova from a “sell” rating to a “hold” rating in a research note on Wednesday, February 7th.

COPYRIGHT VIOLATION NOTICE: “MediciNova, Inc. (MNOV) Stake Boosted by The Manufacturers Life Insurance Company” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/medicinova-inc-mnov-stake-boosted-by-the-manufacturers-life-insurance-company/1960154.html.

About MediciNova

MediciNova, Inc, a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company's product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders consisting of primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction.

Want to see what other hedge funds are holding MNOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MediciNova, Inc. (NASDAQ:MNOV).

Institutional Ownership by Quarter for MediciNova (NASDAQ:MNOV)

Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.